



## Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 20, 2024

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Sep. 20, 2024-- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted three equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in August 2024.

The grants totaled the right to purchase an aggregate of 46,000 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan"). The options were granted on August 30, 2024, the date the Compensation Committee approved the stock option included within the equity inducement and are subject to an exercise price equal to \$11.00, the closing price of Delcath's common stock on August 30, 2024. For each equity award, one-third of the options will vest on the first anniversary of the grant date with the remaining two-thirds of the options vesting in equal monthly installments over the following twenty-four months. The options have a ten-year term and the vesting of the options is subject to the employee's continued employment with Delcath on each vesting date.

The above-described awards were each granted in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.

### About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT™ (melphalan for Injection/Hepatic Delivery System), approved for use in the United States by the Food and Drug Administration, and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), designated under the medical device regulation for use in Europe and the United Kingdom, are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. For more information regarding HEPZATO KIT and its use, including Important Safety Information and Boxed Warning, please visit [HEPZATOKIT.com](https://www.hepzatokit.com). For more information regarding CHEMOSAT and its use, please visit [Chemosat.com](https://www.chemosat.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240920159715/en/): <https://www.businesswire.com/news/home/20240920159715/en/>

### Investor Relations:

ICR Westwicke

[investorrelations@delcath.com](mailto:investorrelations@delcath.com)

Source: Delcath Systems, Inc.